Supplemental Tables 1-4, Supplemental Figures 1-2 from Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non–Small Cell Lung Cancer
Year: 2023
Type: supplementary-materials
Abstract: Supplemental Table 1: Tumor Mutational burden according to individual KRAS mutation. Supplemental Table 2: Multivariate Analysis of duration of platinum/pemetrexed chemotherapy in patients with KRAS-mutant NSCLC Supplemental Table 3: Multivariate Analysis of duration of immunotherapy in patients with KRAS-mutant NSCLC Supplemental Table 4: Multivariate Analysis of Overall Survival from start of Immunotherapy in patients with KRAS-mutant NSCLC Supplemental Figure 1: Duration of platinum/pemetrexed +/- bevacizumab therapy in subset of patients receiving first line therapy for Stage IV disease by KEAP1/NFE2L2 mutations. Supplemental Figure 2: Duration of immune checkpoint inhibitor for treatment of Stage IV disease by different co-occurring mutations (A, STK11 B, KEAP1 or NFE2L2, C, TP53)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361887012